



Octopus AIM VCT 2 plc

Data as at 31 August 2020

About the Product

Octopus AIM VCT 2 plc is a Venture Capital Trust (VCT) which aims to provide shareholders with attractive tax-free dividends and long-term capital appreciation by investing in a diverse portfolio of predominantly AIM-quoted companies.

Risk is spread by investing in a number of different businesses across a range of activities.

Key Facts

Net Assets	£92.7m
Market Cap	£88.2m
Shares Issued	120.8m
Launch Date	2005
Benchmark	FTSE AIM All-Share TR
Number of Holdings	79
Year End	30 November

Current Price

NAV per share*	76.8p
Share price (mid)	73.0p

*NAV reported weekly.

Share buybacks: the VCT can buy back up to 10% of the share capital annually at a 5% discount to NAV, subject to Board approval.

Directors

Keith Mullins (Chairman)
Elizabeth Kennedy
Alastair Ritchie
Andy Raynor

Fees & Codes


Management Fee	2.00%
Total Expense Ratio*	2.00%

ISIN Code	GB00B0JQZZ80
Sedol Code	B0JQZZ8
Ticker (LSE)	OSEC

*Calculated as at 30 November 2019

Performance Overview

Five year performance (%)



	YTD	3 years	5 years	Calendar Year		
				2019	2018	2017
Octopus AIM VCT 2 NAV TR	2.73	3.90	27.58	11.42	-9.66	12.99
Octopus AIM VCT 2 Share Price TR	6.59	6.79	36.42	10.45	-8.88	14.01
FTSE AIM All-Share TR	1.11	-0.95	40.29	13.26	-17.12	25.97
FTSE All-Share TR	-18.54	-8.16	17.32	19.17	-9.47	13.10

Discrete yearly performance (%)

Year to 31 August	2020	2019	2018	2017	2016
Octopus AIM VCT 2 NAV TR	12.30	-14.19	8.24	14.53	8.19
Octopus AIM VCT 2 Share Price TR	15.29	-12.94	6.41	17.93	8.32
FTSE AIM All-Share TR	11.82	-19.95	10.65	29.66	9.25
FTSE All-Share TR	-12.65	0.44	4.68	14.33	11.73

Source: Lipper and Octopus Investments. VCT performance is shown as a simple return comparison between the NAV at the beginning of the period and the NAV, plus any dividends paid out, at the end of the period. VCT share price performance shown includes reinvested dividends. NAV is stated after deduction of fees.

Key Risks

- Your capital is at risk and you may not get back the full amount invested.
- Tax treatment depends on individual circumstances and may be subject to change.
- Investments quoted on AIM are likely to fall and rise in value more than shares listed on the main market of the London Stock Exchange. They may also be harder to sell.
- The availability of tax reliefs also depends on the investee companies maintaining their qualifying status.
- Past performance is not a reliable indicator of future returns.



Investment Enquiries

To speak to any of our fund managers, please call:

0800 316 2394

info@octopusinvestments.com

About the Team

The Octopus Quoted Companies team has a combined experience of more than 100 years. The team, which includes Richard Power, Kate Tidbury, Chris McVey, Edward Griffiths, Stephen Henderson, Mark Symington, Dominic Weller, Jessica Sweeney and Charles Lucas, manage over £1.8 billion in quoted companies, and are also responsible for the Octopus AIM Inheritance Tax Service, FP Octopus UK Micro Cap Growth Fund and FP Octopus UK Multi Cap Income Fund.

Awards



Monthly Commentary

During August, the Net Asset Value (NAV) of the Octopus AIM VCT 2 rose by 6.82%. This compares to an 8.97% increase in the FTSE AIM All Share and a 2.42% increase in the FTSE All Share, both on a total return basis.

Positive news came from online training provider Learning Technologies Group plc, which has seen strong performance in its Software and Platforms division as well as a number of recent meaningful contract wins. Next Fifteen Communications Group plc announced that trading in the first half of the year has been well ahead of management expectations, also leading to full-year earnings forecasts being upgraded by 10%. Digital transformation consultancy The Panoply plc announced a range of contract wins, including a £4.8 million contract with HM Land Registry. Global identity verification business GB Group plc reported that trading in the first quarter was ahead of forecasts, helped by a one-off US customer project. It also announced the acquisition of a minority stake in Singapore-based Credolab for \$3 million. Solid state battery developer Ilika plc announced that its production plans for the revolutionary Stereax battery remain on track. Technical patent and IP translator RWS Holdings plc announced a transformational merger with main-listed SDL plc via an all-share transaction. The transaction will create the world's leading language services and technology group and is expected to be earnings-enhancing in the first full year post completion of the deal. We also had positive news from our medical portfolio. Contract research organisation Ixico plc announced a strong trading update, materially ahead of market expectations and a 50% upgrade to profits. EKF Diagnostics plc announced a strategic investment into Trellus Health. Diagnostics specialist Renalytix AI plc announced that it has filed a submission seeking clearance of Kidney IntelX with the US Food and Drug Administration. Less positive news came from Craneware plc, who had to pull an £80 million fund raising at the last minute as acquisition target VitalWare announced it had been bought by Health Catalyst. Shares in discretionary fund manager Brooks Macdonald Group plc were also weak over the month despite an absence of news flow and we believe the shares are under-valued at current levels.

A joint fundraise of £20 million together with Octopus AIM VCT plc has been announced. We are excited for the ongoing opportunities in UK smaller companies and thank our investors for their long-term support.

5-Year Dividend History

Pay Date	Type	Dividend
16 Oct 2015	Interim	2.00p
20 May 2016	Final	2.00p
30 Sep 2016	Interim	2.00p
28 Apr 2017	Final	2.00p
29 Sep 2017	Interim	2.10p
18 May 2018	Final	2.10p
18 Oct 2018	Interim	2.10p
24 May 2019	Final	2.10p
07 Nov 2019	Special	3.90p
07 Nov 2019	Interim	2.10p
22 May 2020	Final	2.10p

The Board has a policy of providing shareholders with a yield of 5% based on share price, subject to a minimum payment of 3.6p per share per year.

Portfolio Analysis

Top Ten Equity Holdings (%)

Learning Technologies Group	5.1
GB Group	4.9
Breedon	4.1
Ergomed	3.9
FP Octopus UK Micro Cap Growth	3.6
Craneware	2.8
EKF Diagnostics Holdings	2.6
Ixico	2.4
Trackwise	2.0
Judges Scientific	2.0
Total	33.4

Top Ten Sectors (%)

Software & Computer Services	16.4
Pharmaceuticals & Biotechnology	12.8
Support Services	8.0
Health	6.0
Unit Trusts	5.1
Electronic & Electrical	4.8
Construction & Building	4.1
General Retailers	3.9
Telecommunication Services	2.9
Other	2.8
Total	66.8

Glossary

Index

A representative portfolio of securities created to represent a particular market or a portion of it.

Net Asset Value (NAV)

The price-per-share of a fund or other investment. The per-share amount of the fund is based on the total value of all the securities in its portfolio, any liabilities the fund has and the number of fund shares outstanding.

Total Return (TR)

The gain or loss derived from an investment over a specified period of time. This figure includes interest, capital gains, dividends, and income distributions realised over that time period.

Important Information

Personal opinions may change and should not be seen as advice or a recommendation. We do not offer investment or tax advice. We recommend investors seek professional advice before deciding to invest. Regarding VCTs, this advertisement is not a prospectus and you should only subscribe for shares on the basis of information contained in the prospectus and the Key Information Document. For other investments, investors should read the product brochure before deciding to invest. These documents are available at octopusinvestments.com. Issued by Octopus Investments Limited, which is authorised and regulated by the Financial Conduct Authority. Registered office: 33 Holborn, London, EC1N 2HT. Registered in England and Wales No. 03942880. We record telephone calls. CAM010149. Issued: September 2020.